The completion of enrollment in the Phase 2 PAVIA clinical trial of EYP-1901 is a significant milestone for EyePoint Pharmaceuticals. This progress indicates that the company is moving forward with its drug development program, which could potentially lead to positive results and increased investor interest in the stock. As a result, the stock price is likely to go up in the short term.